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ABSTRACT The appearance of drug-resistant strains of
viral pathogens is a major difficulty confounding current
efforts to block viral infections. The identification and analysis
of mutations responsible for drug resistance can provide im-
portant dues helpful in understanding the mhanisms of
resistance and in the eventual development of better therapies.
We have used a direct screening method to scan libraries of
mutagenized genes encoding the reverse transcriptase of hu-
man immunodeficiency virus type 1, and have recovered a
variant enzyme that is resistant to the chain-terminator inhib-
itor 2',3'-dideoxyguanosine triphosphate. The single substitu-
tion mutation in this variant conferred broad crossresistance to
a variety of other antiviral compounds currently in clnil
trials. Virus carrying the mutation was fully infectious in
cultured human lymphocytes. The replication of the mutant
virus was highly resistant to phosphonoforic acid but did not
show increased resistance to the prodrug dideoxyguanosine.
The replication of the retroviral genome includes several
reactions, each catalyzed by specific viral gene products, that
are distinctive from steps in the normal replication ofthe host
cell. Prominent among these unusual reactions is reverse
transcription, the synthesis of a DNA copy of the RNA
genome, mediated- by the virion-associated enzyme reverse
transcriptase (RT). Because this reaction is so central to
retroviral replication, and because it is at least presumably
dispensable for the host, it is a prime target of antiviral drugs
aimed at blocking viral infection. Many of these compounds
block the DNA polymerase activity of RT by chain termina-
tion: when incorporated into the growing 3' end of the DNA
product, these compounds block further elongation. The
prodrugs 3'-azido-3'-deoxythymidine (zidovudine; AZT),
dideoxycytidine (ddC), and dideoxyinosine (ddI) are all con-
verted to the corresponding 5'-triphosphates by host kinases
and then presumably incorporated into DNA by RT to block
viral DNA synthesis.
Resistance to antiviral drugs arises rapidly in viruses of
many types and can severely limit the use of these com-
pounds in antiviral therapy (1, 2). Variants of human immu-
nodeficiency virus type 1 (HIV-1) profoundly resistant to
AZT have been isolated from AIDS patients undergoing
prolonged treatment (3) and have been shown to contain
specific mutations in the region ofthe viral pol gene encoding
RT (4). These mutations are sufficient, when introduced into
a cloned wild-type genome, to confer on the virus drug
resistance for replication in culture. Curiously, the mutant
RT isolated from the resistant virus, or expressed in bacterial
systems, did not manifest any detectable changes in its
sensitivity to inhibition by AZTTP as measured in standard
DNA polymerase assays in vitro. This result suggests that
some aspect of the activity of RT in vivo is significantly
different from that measured in vitro.
A large number of mutant RTs have been generated by
site-specific mutagenesis of cloned DNAs that express the
enzyme in heterologous systems (5-7). Some mutants dis-
playing altered sensitivity to the chain-terminator inhibitor
AZTTP have been recovered in these efforts and character-
ized (8), and the effects ofthe mutations on the viral life cycle
were determined after transfer of the mutations to viral
genomes (9). While some of the mutant genomes could not
replicate, others were viable and could be tested for resis-
tance to the prodrug inhibitor for their replication in cell
culture. The mutant viruses were not resistant in culture, and
in fact some were hypersensitive to AZT (9). The findings
further support the conclusion that there must exist profound
differences between DNA polymerase assays carried out in
vitro and the process of DNA synthesis in the infected cell.
The isolation of more such mutants resistant to the nucle-
oside analogues under evaluation for antiviral therapy is likely
to be important in predicting the efficacy of these drugs, in
determining the crossresistance of these mutant viruses to
other drugs, in defining the spectrum of changes in the viral
genome that can produce resistance, and in defining the site of
action of the drugs on the RT enzyme. To accelerate the
isolation and characterization of such drug-resistant mutants,
we developed an in situ screening method for assaying the RT
activity present in individual bacterial colonies expressing the
cloned HIV enzyme (10). We have now used the method to
isolate and characterize a mutant clone encoding a variant
enzyme resistant to the chain-terminator inhibitor 2',3'-
dideoxyguanosine 5'-triphosphate (ddGTP).
MATERIALS AND METHODS
Isolation of Mutant Clone. A plasmid expressing wild-type
HIV RT, pHRTRX2 (11), was introduced into an Escherichia
coli mutator strain carrying the mutDS mutation (strain LE30;
gift of L. Enquist, DuPont) and was propagated in nutrient-
poor medium (M9 plus Casamino acids). Cultures were
grown for 14 hr in rich medium (Luria broth) to induce
mutations, and plasmid DNA was prepared and used to
transform nonmutator bacteria (HB101). Colonies were
grown on plates containing M9 salts plus Casamino acids and
tryptophan and were screened by the in situ colony screening
procedure (10).
Inhibition of RT Activity in Vitro by ddGTP. Assays were
performed with extracts fromDNA polymerase I-deficient E.
coli C2110 carrying a single chromosomally integrated copy
of the appropriate expression plasmid, encoding either the
Abbreviations: AZT, 3'-azido-3'-deoxythymidine; PFA, phosphono-
formic acid; RT, reverse transcriptase.
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wild-type or the mutant RT. The bacteria carrying the re-
spective constructs were induced by tryptophan starvation
for the production of the fusion protein, and extracts were
prepared (6). The assays were carried out in duplicate in 50-,Al
of 50 mM Tris Cl. pH 8.0/10 mM MgCl2/20 mM dithiothrei-
tol/60 mM NaCl/0.05% Nonidet P-40 containing poly(rC) (10
,tg/ml), oligo(dG) (5 ,tg/ml), 4.7 AuM [a-32P]dGTP [1 Ci (37
GBq)/mmol)], and various concentrations of ddGTP.
Inhibition by Other Compounds: Assays for Crossresistance.
Except as noted, conditions were as for inhibition by ddGTP.
For inhibition by ddTTP, template and primer were poly(rA)
and oligo(dT), and substrate was [a-32P]dTTP (5.6 ,uM); for
ddCTP, template and primer were poly(rI) and oligo(dC),
substrate was [a-32P]dCTP (5 MM), and divalent cation was
MnCl2 (0.1 ,M); for ddATP, template and primer were
poly(rU) and oligo(dA), substrate was [a-32P]dATP (5 AM),
and divalent cation was MnCl2 (2 mM). For both phosphono-
formic acid (PFA) and AZTTP, primer and template were
poly(rA) and oligo(dT), substrate was [a-32P]dTTP (5.6 ,uM),
and cation was MgCl2 (10 mM). To test for dependence of
pddGTPr-1 RT activity on divalent cation, template and
primer were poly(rA) and oligo(dT), and substrate was
[a-32P]dTTP (5.6 ,uM).
Mapping of Mutation in ddGTPr-l Clone. Two sets of
plasmids were constructed by exchanging fragments between
the wild-type and mutant clone. In the first set, the region
encoding RT, flanked by unique BamHI and Xba I sites, was
exchanged between the two parents to produce plasmids EX
1 and EX 2. In the second set, a fragment containing a
478-base-pair BamHI-EcoRV portion of the gene was ex-
changed to produce plasmids EX 3 and EX 4. Enzymes
encoded by each plasmid were tested for sensitivity to ddGTP
as described above. The nucleotide sequence of both strands
of the BamHI-EcoRV fragment was determined (12, 13).
Analysis of Kinetics of Viral Replication. Jurkat-tat cells (14)
were infected with virus or transfected by the DEAE-dextran
method and allowed to recover for 24 hr, and 106 cells (0.5 ml)
were distributed in triplicate into medium (RPMI 1640/10%
fetal bovine serum with antibiotics; 4.5 ml) containing various
levels of antiviral drugs, ensuring identical input virus inocula
for the different drug doses. Three milliliters of the medium
was replaced after 24 hr and subsequently every 2-3 days (for
medium with PFA) or daily (for medium with ddG). Cells
were split 1:2 or 1:3 when their density exceeded 4-5 x 106
per ml and were handled identically for all samples within an
experiment. Supernatants were analyzed for RT activity
under standard conditions. Radioactivity incorporated was
internally normalized to the peak activity for the given viral
clone in the presence of no antiviral drug; the peaks were
similar between mutant and wild type, =5 x 104 cpm/ml of
unconcentrated supernatant. Mock infection or transfection
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FIG. 1. Inhibition of wild-type (pHRTRX2, [D) and the pddGTPr-1
variant (*) RT by ddGTP.
After induction of the trp operon, the bacteria on the filter
were screened for RT activity in the presence of 1 ,uM
ddGTP, a level that inhibits the wild-type enzyme ==95%.
Of 50,000 colonies screened, we recovered one clone,
pddGTPr-1, that consistently tested as drug-resistant.
Cultures containing the mutant and wild-type clones were
induced for expression, lysates were prepared, and conven-
tional RT assays were carried out in various concentrations
of ddGTP (Fig. 1). The IC50 value was at least 10 times higher
for the mutant enzyme. The overall yield of enzyme present
in the extracts was comparable to the wild type, based on
Coomassie blue staining of the proteins after PAGE. The
specific activity of the mutant enzyme in the absence of
inhibitor was similar to (50-100%) that of the wild type.
To identify the mutation responsible for the resistance,
chimeric RT plasmids were first generated by exchanging
DNA fragments between pddGTPr-1 and the wild-type par-
ent (Fig. 2). The enzymes encoded by these hybrid genes
were then tested for resistance in the standard assay. In the
first pair of hybrids, created by exchanging the entire RT
sequence, the drug-resistance phenotype was found to seg-
regate with the mutant RT fragment, demonstrating that the
mutation lies in the RT coding region and not in the trpE
fusion partner or the regulatory regions. A second pair of





Isolation and Characterization of Mutant HIV-1 RT. To
isolate a drug-resistant variant of the HIV-1 RT, we gener-
ated a library of random mutants and screened for the desired
phenotype. The parent for the mutagenesis was the bacterial
expression plasmid pHRTRX2, expressing the HIV RT as an
enzymatically active fusion protein under control of the trp
operon (11). The plasmid was mutagenized by transfer into a
mutator strain of bacteria (LE30) carrying the mutD5 allele
(15) and growth in high levels of thymidine for 14 hr. Under
these conditions, a lacZ indicator gene on a control plasmid
was mutagenized sufficiently in parallel experiments to yield
0.2-1.0% Lac- mutants. Nonmutator bacteria (HB101) were
then transformed with pools of the mutagenized DNA, plated
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FIG. 2. (A) Localization of the mutation in the pddGTPr-1 RT by
construction of hybrid RTs. Portions of the wild-type and the variant
plasmid were exchanged by using selected restriction sites. (B)
Identity of the point mutation.
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portion of the gene, upstream of the EcoRV site at position
427. Sequence analysis showed a single nucleotide change in
this portion of the gene. The mutation was an A-to-G tran-
sition, changing the GAA triplet (Glu89) to GGA (Gly). Thus,
substitution of a single residue in the protein was responsible
for the altered phenotype.
Further Characterization of the ddGTPr-1 Mutation. The
mutant enzyme was tested for crossresistance to a spectrum
ofother inhibitors ofDNA polymerases using the appropriate
ribohomopolymner.templates. To reduce the background ac-
tivity of DNA polymerase I detected on some of the tem-
plates, the pddGTPr-1 construct was transferred to a PoLA-
independent plasmid and introduced into a PolA- bacterial
host (strain' C2110; ref. 16). Extracts were prepared and
assayed in the standard reaction in the presence of various
levels of inhibitors. In each case, the enzymes were assayed
on the appropriate substrates with optimal concentrations of
divalent cation (Fig. 3; summarized in Table 1). The mutant
enzyme was approximately as resistant to the chain termi-
nators ddTTP and ddCTP as it was to ddGTP, with IC50
values 8 and 20 times that of the wild type. The mutant was
marginally resistant to ddATP and showed significant resis-
tance to the clinically important (17) compound AZTTP (Fig.
3B). Studies with other AZTTP-resistant RTs have shown
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Table 1. Resistance of RT to various inhibitors
ICR,, A&M Fold
Inhibitor Wild type Variant resistance
ddGTP 0.04 0.5 12.5
ddATP 0.05 0.15 3
ddTTP 0.10 2.0 20
ddCTP 0.05 0.4 8
PFA 0.20 5.0 25
AZTTP 0.05 0.25 5
phosphate analog (8). The pddGTPt-1 enzyme was highly
resistant to PFA, with an IC50 value 25-fold higher than the
wild-type enzyme assayed on poly(rA) template. The mutant
enzyme was extraordinarily resistant to PFA when assayed
on other templates, with an IC50 value as much as 500-fold
higher on the poly(rC) template (data not shown).
The RT of HIV-1, like most other RTs, displays a char-
acteristic preference for Mg2+ as divalent cation for maximal
activity; the RTs of the murine leukemia viruses are unusual
in preferring Mn2+ on homopolymer templates. To test the
pddGTPr-1 mutant for altered cation requirements, extracts
were assayed under standard conditions but with various
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FIG. 3. Properties of wild-type (o) and pddGTPr-1 (*) RT. (A) Crossresistance to ddNTPs. (B) Crossresistance to other inhibitors. (C)
Dependence on divalent cation.
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slightly low or normal activity compared with the wild-type
at all concentrations of Mg2" but was significantly more
active than wild type with Mn2+ (Fig. 3C). The overall shapes
of the curves, and the optimal concentrations, were similar
for the two enzymes.
Replication of Viruses Bearing the ddGTPr-1 Mutation. To
determine whether the mutation in pddGTPr-1 was compat-
ible with virus replication, we excised a DNA fragment
containing the mutation from pddGTPr-1 and used it to
replace the corresponding fragment oftwo complete proviral
DNAs, pHXB2 and pR7/3/BH10 (18,19). The mutant DNAs
were introduced into Jurkat-tat cells (14), and the appearance
of virus was monitored by examination of the cultures for
cytopathic effect and by assay for the appearance of RT
activity in the culture medium. The mutant DNAs induced
the formation of virus with kinetics and yield indistinguish-
able from those of the respective wild-type parental DNAs.
There was no discernible difference in the cytopathic effect
induced by the corresponding mutant and wild-type viruses.
To determine whether the virion-derived enzyme would
display the same altered drug sensitivity as the bacterially
derived enzyme, we harvested virus from the culture super-
natants and carried out RT assays in various levels ofddGTP.
The enzyme extracted from the mutant virions displayed the
same profile of increased drug resistance as the mutant
bacterial enzyme (data not shown). Thus, the mutation was
fully compatible with normal virus replication, was stably
retained by the mutant virus during replication in culture, and
conferred the same resistance on the enzyme, as measured by
assays in vitro.
To determine whether the mutant viruses would manifest
drug resistance in their replication in culture, we measured
the kinetics of release of virus in infected cultures maintained
in various levels of drugs. Virus replication was initiated in
human lymphocytic cell lines either by transfection with
Wild-type virus
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mutant DNA or by infection with virus supernatants, and
after 24 hr the cultures were divided into replicate dishes. The
cultures were maintained in medium with various levels of
two inhibitors: the cognate prodrug, ddG, and the drug
showing the highest crossresistance, PFA. Culture superna-
tants were harvested at various times postinfection and
assayed under standard conditions for virion-associated RT.
The mutant virus was profoundly resistant to PFA as com-
pared with the wild type (Fig. 4A). In cultures containing 10
and 100 MIM PFA, replication of the wild-type virus was
significantly slowed, while that of the mutant was unaffected;
at 1000 uM PFA, replication of the wild-type virus was
almost completely suppressed, while that of the mutant was
only delayed. We conclude that the mutation, isolated on the
basis of its effect on RT activity in vitro, could confer a
biologically significant phenotype on virus replication in vivo.
In contrast to these results with PFA, the mutant virus was
not detectably more resistant to ddG than the wild type (Fig.
4B). As ddG was increased, both wild-type and mutant
viruses were similarly inhibited: at 5IMM drug, the replication
of both viruses was delayed, and at 50 MLM drug, replication
of both was strongly suppressed. Thus, significant resistance
to some drugs, but not all, was conferred on the virus by the
mutation. This finding is similar to results with several
AZTTP-resistant mutants (8).
DISCUSSION
Previous efforts to isolate drug-resistant variants of the
HIV-1 RT have depended either on the recovery of drug-
resistant virus from infected patients (3) or on in vitro
mutagenesis of HIV RT expression constructs and subse-
quent testing of individual mutants for resistance (8). The
direct screening of large numbers of randomly mutagenized
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FIG. 4. Kinetics of rep-
lication of HIV-1 contain-
ing the ddGTPr-1 mutation,
determined in the presence
of various levels of inhibi-
tors. (A) RT released after
infection of lymphocytes
with either wild-type or
ddGTP-resistant HIV-1
(R3BH10) as indicated, in
the presence of 0 MM (*),
10 MM (o), 100 MM (<), or
1000 MM (8) PFA. (B) RT
released after transfection
oflymphocytes with cloned
proviral DNAs and growth
in the presence of0MM (0),
0.1 AM (*), 5 AM (o), or 50
MM (') ddG. Aliquots of
the supernatant culture me-
dium were assayed for RT
activity as a measure of
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desired properties. The ease and relatively high frequency (1
in 50,000) with which a ddGTP-resistant mutant was recov-
ered in this study suggests that similar mutants resistant to
many compounds can also be generated.
RT is an important target for antiviral therapy directed
against AIDS (20), and thus it is noteworthy that a single point
mutation was able to confer on the HIV-1 RT a significant
level of drug resistance. The mutation frequency of retroviral
replication (21, 22), attributable to the high error rate of RT
(23, 24), is such that variants arise extremely rapidly and
come to predominate in patients undergoing antiviral treat-
ment. It would be alarming if such simple mutations can
confer a broad crossresistance to other inhibitors in vivo. The
result suggests that mutations like that in pddGTPr-1 might
appear as combination drug treatments are applied, and that
drugs of distinct classes should be used to avoid the appear-
ance of viruses exhibiting simultaneous resistance (25, 26).
We speculate that the mutation affects the binding of all
these phosphorylated inhibitors without severely altering the
binding of the natural dNTPs. Thus, the natural Glul residue
may be located at or near the triphosphate binding site or may
indirectly perturb the structure of that site. That the mutation
affects the requirement for divalent cation, presumably
bound to the triphosphate, supports this notion. This residue
is conserved among the known isolates of HIV-1, HIV-2, and
various simian immunodeficiency viruses, though not among
more distantly related retroviruses (27). The mutation is near,
though not identical, to some of the mutations found in
AZT-resistant variants ofHIV-1 isolated from patients, caus-
ing changes at amino acids 67, 70, 215, and 219 (ref. 4).
Ultimately, when the three-dimensional structure of a mem-
ber of the RT family is known, mutations like that in
pddGTPr-1 will be important in locating binding sites and
understanding the detailed mechanism of action of the en-
zyme.
It is curious that the ddGTP-resistance mutation confers on
the virus resistance to PFA, but not to ddG, for its replication
in culture. Similarly, mutants of HIV RT that are resistant to
AZTTP have been found not to confer resistance to AZT on
the virus (9). It is possible that in the case ofchain-terminator
inhibitors in general, resistance measured in vitro may not
correlate with resistance measured in vivo; the assay condi-
tions used in the in vitro assays may simply be inappropriate,
but alternatively it may be that there is a fundamental
difference in the mechanism of action of the drugs between
the two settings. It may be, for example, that the primary
mechanism of inhibition in vivo is not through chain termi-
nation alone but rather through effects on enzyme elongation
rate or processivity, or on specific steps in retroviral reverse
transcription such as strong stopDNA translocation. It might
also be that the presence of other viral proteins at the time of
reverse transcription in vivo could significantly alter the
response ofthe enzyme to inhibitors. The approach described
here will allow the rapid characterization of mutants of RT
resistant to various clinically relevant drugs and may assist in
the understanding ofthe precise mechanisms by which chain-
terminator inhibitors interfere with HIV replication.
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